drugset / Trial / NCT00764751

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

NCT00764751 ↗

Phase 2 Completed 51 enrolled LEO Pharma
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.

Timeline

Start
2008-09
Primary completion
2008-12
Completion
2009-01

Outcome

Missed primary endpoint

registry Group B: LEO 19123 vs Group B: LEO 19123 Vehicle; p = 0.07; Mean Difference (Final Values) -17.1 (95% CI -36.0 to 1.9) NCT00764751 ↗

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcipotriene Other / unclassified — —
Subject Calcipotriol Small molecule — —
Subject LEO80122 Unknown — —

Indications